Known targets — ChEMBL curated mechanism
fasrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmB1rpmB2rpmCrpmDrpmErpmFrpmG1rpmG2rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsR1rpsR2rpsSrpsTrpsZ
The experimentally established mechanism targets of Pyrazinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | MC4R | P32245 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | MC3R | P41968 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.68 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.68 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrazinamide SCHEMBL27524986 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL32667957 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL5010455 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL27474998 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL11616580 | 0.98 | ADORA3 (0.91) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL18364991 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL18364989 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL29518620 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL29408106 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL24102 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-01 | — | — | US | claimed |
| CN-100360522-C | Novel compounds having selective inhibiting effect at GSK3 | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | CN | claimed |
| CN-1726210-A | Novel compounds having selective inhibiting effect at GSK3 | ASTRAZENECA AB (SE) | 2006-01-25 | — | — | CN | claimed |
| EP-1575939-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004055006-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| CN-1134278-A | Aerosol for preventing and curing pulmonary tuberculosis and its preparing method and synergy method | CONG FANZI (CN) | 1996-10-30 | — | — | CN | claimed |
| CN-1105236-A | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof | CONG FANZI (CN) | 1995-07-19 | — | — | CN | claimed |
| CN-118829631-A | Pyrazine compounds as FLT3 inhibitors | 拜欧米富士恩公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-113264921-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-01 | — | — | US | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-113880843-B | Heterocyclic compound and application thereof | 武汉朗来科技发展有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-1680377-A | 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | SERVIER LAB (FR) | 2005-10-12 | — | — | CN | disclosed |
| CN-1147489-C | New bicyclo aminopyrazineone compound, its producing process and medical composition containing them | ɪά��ʵ���� | 2004-04-28 | — | — | CN | disclosed |
| CN-1277198-A | New bicyclo aminopyrazineone compound, its producing process and medical composition containing them | ADIR (FR) | 2000-12-20 | — | — | CN | disclosed |
| CN-1134278-A | Aerosol for preventing and curing pulmonary tuberculosis and its preparing method and synergy method | CONG FANZI (CN) | 1996-10-30 | — | — | CN | disclosed |
| CN-1105236-A | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof | CONG FANZI (CN) | 1995-07-19 | — | — | CN | disclosed |
| CN-1023479-C | Process for preparing monoamide derivatives of ethylenediamine | HOFFMANN LA ROCHE (CH) | 1994-01-12 | — | — | CN | disclosed |
| CN-85107182-A | Process for preparing monoamide derivatives of ethylenediamine | — | 1987-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | MLKL, PCSK9, CTSA | ADORA3 2162/4885TSHR 4534/4885MC4R 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.